exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089189 RNA Name: hsa-miR-574-5p RNA Type: miRNA Chromosome: chr4 Starnd: + Coordinate: Start Site(bp): 38868056 End Site(bp): 38868078 External Links: hsa-miR-574-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CCDC88C chr14 91271323 91417844 - CARMIL1 chr6 25279078 25620530 + AHCYL1 chr1 109984765 110023742 + ARID3A chr19 925781 975939 + CHD7 chr8 60678740 60868028 + IDH3A chr15 78131498 78171945 + FAM102A chr9 127940582 127980989 - EEF2K chr16 22206278 22288738 + LRP8 chr1 53242364 53328469 - SMCO4 chr11 93478472 93543391 - ALDOA chr16 30064164 30070457 + ZNF621 chr3 40524878 40574685 + MAP7D1 chr1 36155579 36180849 + RAB10 chr2 26034084 26137454 + TACC1 chr8 38728186 38853028 + KLF11 chr2 10042849 10054836 + TEAD1 chr11 12674421 12944737 + MGRN1 chr16 4616493 4690974 + SLC9A1 chr1 27098809 27166981 - FNDC3A chr13 48975912 49209779 + SLC25A43 chrX 119399336 119454478 + CTSD chr11 1752755 1764573 - PHF20L1 chr8 132775358 132848807 + DCAF8 chr1 160215715 160262549 - PIK3R3 chr1 46040140 46133036 - RHOU chr1 228735479 228746664 + GALNT3 chr2 165747588 165794659 - HOXC8 chr12 54008985 54012769 + NID1 chr1 235975830 236065109 - WSB2 chr12 118032694 118062430 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005394.2 chr19 28435388 28727680 - AC021092.1 chr19 44103007 44113183 - AL358472.3 chr1 153966516 153966930 + DSCAM-AS1 chr21 40383083 40385358 + NEAT1 chr11 65422774 65445540 + SNHG7 chr9 136721366 136728184 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.